JP2002542196A - 細胞容量調節ヒトキナーゼｈ−ｓｇｋのインヒビター含有医薬 - Google Patents

細胞容量調節ヒトキナーゼｈ−ｓｇｋのインヒビター含有医薬

Info

Publication number
JP2002542196A
JP2002542196A JP2000611917A JP2000611917A JP2002542196A JP 2002542196 A JP2002542196 A JP 2002542196A JP 2000611917 A JP2000611917 A JP 2000611917A JP 2000611917 A JP2000611917 A JP 2000611917A JP 2002542196 A JP2002542196 A JP 2002542196A
Authority
JP
Japan
Prior art keywords
sgk
expression
kinase
cell volume
volume regulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000611917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002542196A5 (pt
Inventor
フローリアン・ラング
ジークフリート・ヴァルデガー
カルシュテン・ヴァーグナー
シュテファン・ブレーア
カーリン・クリンゲル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002542196A publication Critical patent/JP2002542196A/ja
Publication of JP2002542196A5 publication Critical patent/JP2002542196A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000611917A 1999-04-20 2000-04-19 細胞容量調節ヒトキナーゼｈ−ｓｇｋのインヒビター含有医薬 Pending JP2002542196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19917990.5 1999-04-20
DE19917990A DE19917990A1 (de) 1999-04-20 1999-04-20 Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
PCT/EP2000/003578 WO2000062781A1 (de) 1999-04-20 2000-04-19 Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk

Publications (2)

Publication Number Publication Date
JP2002542196A true JP2002542196A (ja) 2002-12-10
JP2002542196A5 JP2002542196A5 (pt) 2007-06-14

Family

ID=7905297

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000611917A Pending JP2002542196A (ja) 1999-04-20 2000-04-19 細胞容量調節ヒトキナーゼｈ−ｓｇｋのインヒビター含有医薬

Country Status (18)

Country Link
EP (1) EP1171131A1 (pt)
JP (1) JP2002542196A (pt)
KR (1) KR100718900B1 (pt)
CN (1) CN1351496A (pt)
AU (1) AU779941B2 (pt)
BR (1) BR0009914A (pt)
CA (1) CA2369078A1 (pt)
CZ (1) CZ20013778A3 (pt)
DE (1) DE19917990A1 (pt)
HU (1) HUP0200819A3 (pt)
MX (1) MXPA01010588A (pt)
NO (1) NO20015054L (pt)
PL (1) PL198427B1 (pt)
RU (1) RU2288718C9 (pt)
SK (1) SK14972001A3 (pt)
UA (1) UA79066C2 (pt)
WO (1) WO2000062781A1 (pt)
ZA (1) ZA200108610B (pt)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082402A1 (ja) * 2004-03-02 2005-09-09 Hokkaido Technology Licensing Office Co., Ltd. 臓器線維症予防・治療剤
JP2007527875A (ja) * 2004-03-11 2007-10-04 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 線維症を抑制するための方法
JP2007529423A (ja) * 2004-03-11 2007-10-25 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 血清・グルココルチコイド誘導性キナーゼのモジュレータの使用を含む、神経精神疾患を治療するためのグルタミン酸受容体の調節方法
JP2008504241A (ja) * 2004-06-26 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング オルト置換ｎ’−ベンジリデン−（３−ヒドロキシフェニル）アセトヒドラジド類
JP2008535833A (ja) * 2005-04-04 2008-09-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 特にｓｇｋについてのキナーゼ阻害剤としてのアシルヒドラジド類
JP4762552B2 (ja) * 2003-03-03 2011-08-31 フロリアン ラング、 診断用および治療用標的としてのｓｇｋ１

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042137A1 (de) * 2000-08-28 2002-03-14 Florian Lang sgk2 und sgk3 als diagnostische und therapeutische Targets
DE10113876A1 (de) * 2001-03-21 2002-09-26 Eberhard Karls Uni Medizinisch Quantitative diagnostische Analyse der Hypertonie
DE60233398D1 (de) * 2001-04-27 2009-10-01 Cold Spring Harbor Lab Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstörungen durch veränderung der atypischen pkm-aktivität
DE10149393A1 (de) * 2001-09-28 2003-04-24 Florian Lang sgk1 als diagnostisches und therapeutisches target
DE10225844A1 (de) * 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets
DE10305212A1 (de) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
DE10346913A1 (de) 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
WO2005106491A2 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005118832A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl)
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
DE102005001053A1 (de) * 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
DE102005035742A1 (de) * 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
DE102005039541A1 (de) * 2005-08-22 2007-03-22 Merck Patent Gmbh 3-Oxo-indazol-quadratsäurederivate
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
DE102008010362A1 (de) 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen
DE102008010361A1 (de) 2008-02-18 2009-08-20 Merck Patent Gmbh sgk1-Inhibitoren zur Prophylaxe und/oder Therapie von viralen Erkrankungen und/oder Karzinomen
DE102008010363A1 (de) 2008-02-18 2009-08-20 Lang, Florian, Prof. Dr.med. Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008059133A1 (de) 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorphenyl-diacylhydrazid-derivate
EP2637650A2 (en) 2010-11-10 2013-09-18 National Jewish Health Methods to test allergic conditions
CN107875153A (zh) * 2017-11-16 2018-04-06 上海壹志医药科技有限公司 去甲白屈菜红碱的药物用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPH1192401A (ja) * 1997-06-27 1999-04-06 Smithkline Beecham Corp ヒト血清グルココルチコイドにより調節されるキナーゼ、慢性腎不全に対する標的

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US5874464A (en) * 1995-01-13 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Conformationally constrained diacylglycerol analogues
AU6888196A (en) * 1995-08-11 1997-03-12 Yale University Glycosylated indolocarbazole synthesis
ES2170390T3 (es) * 1996-05-30 2002-08-01 Aventis Pharma Inc Fluorenonas alquiloxiamino-substituidas y su uso como inhibidores de la proteina kinasa-c.
EP0889127A1 (en) * 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/threonine protein kinase (H-SGK2)
CO4940430A1 (es) * 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPH1192401A (ja) * 1997-06-27 1999-04-06 Smithkline Beecham Corp ヒト血清グルココルチコイドにより調節されるキナーゼ、慢性腎不全に対する標的

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4762552B2 (ja) * 2003-03-03 2011-08-31 フロリアン ラング、 診断用および治療用標的としてのｓｇｋ１
WO2005082402A1 (ja) * 2004-03-02 2005-09-09 Hokkaido Technology Licensing Office Co., Ltd. 臓器線維症予防・治療剤
JP2007527875A (ja) * 2004-03-11 2007-10-04 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 線維症を抑制するための方法
JP2007529423A (ja) * 2004-03-11 2007-10-25 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 血清・グルココルチコイド誘導性キナーゼのモジュレータの使用を含む、神経精神疾患を治療するためのグルタミン酸受容体の調節方法
JP2008504241A (ja) * 2004-06-26 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング オルト置換ｎ’−ベンジリデン−（３−ヒドロキシフェニル）アセトヒドラジド類
JP2008535833A (ja) * 2005-04-04 2008-09-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 特にｓｇｋについてのキナーゼ阻害剤としてのアシルヒドラジド類

Also Published As

Publication number Publication date
EP1171131A1 (de) 2002-01-16
PL352547A1 (en) 2003-08-25
KR100718900B1 (ko) 2007-05-17
PL198427B1 (pl) 2008-06-30
NO20015054D0 (no) 2001-10-17
CN1351496A (zh) 2002-05-29
NO20015054L (no) 2001-12-14
MXPA01010588A (es) 2004-09-06
DE19917990A1 (de) 2000-11-02
CA2369078A1 (en) 2000-10-26
AU4297200A (en) 2000-11-02
AU779941B2 (en) 2005-02-17
HUP0200819A2 (hu) 2002-07-29
HUP0200819A3 (en) 2009-08-28
RU2288718C9 (ru) 2008-04-27
SK14972001A3 (sk) 2002-06-04
CZ20013778A3 (cs) 2002-06-12
BR0009914A (pt) 2002-01-08
RU2288718C2 (ru) 2006-12-10
ZA200108610B (en) 2002-01-02
KR20020012172A (ko) 2002-02-15
UA79066C2 (en) 2007-05-25
WO2000062781A1 (de) 2000-10-26

Similar Documents

Publication Publication Date Title
JP2002542196A (ja) 細胞容量調節ヒトキナーゼｈ−ｓｇｋのインヒビター含有医薬
EP3389725B1 (en) Compositions and methods for treatment of central nervous system diseases
US6887853B2 (en) Use of geldanamycin and related compounds for treatment of fibrogenic disorders
Boylan et al. Overexpression of the cellular retinoic acid binding protein-I (CRABP-I) results in a reduction in differentiation-specific gene expression in F9 teratocarcinoma cells.
de Frutos et al. NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with α-actin up-regulation
US6214569B1 (en) Methods for screening for inhibitors of Alzheimer β-peptide filament formation
Venkatesh et al. Differential glucocorticoid regulation of the pulmonary hydrophobic surfactant proteins SP-B and SP-C
Watlington et al. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats
Nakhoul et al. Regulation of sodium transport in M-1 cells
Maione et al. Ca2+ dysregulation in cardiac stromal cells sustains fibro-adipose remodeling in Arrhythmogenic Cardiomyopathy and can be modulated by flecainide
US20050064501A1 (en) Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk
Suda et al. Effects of corticotropin-releasing hormone and dexamethasone on proopiomelanocortin messenger RNA level in human corticotroph adenoma cells in vitro.
Koyama et al. Premature Growth Plate Closure Caused by a Hedgehog Cancer Drug Is Preventable by Co‐Administration of a Retinoid Antagonist in Mice
Nicolas et al. A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics
Belluardo et al. Nicotine-induced fibroblast growth factor-2 restores the age-related decline of precursor cell proliferation in the subventricular zone of rat brain
AU2003238462A1 (en) Sgk and nedd used as diagnostic and therapeutic targets
Toutenhoofd et al. Regulation of calmodulin mRNAs in differentiating human IMR-32 neuroblastoma cells
Pácha et al. Carbenoxolone accelerates maturation of rat intestine
Verhoeven et al. Nimesulide inhibits platelet-activating factor synthesis in activated human neutrophils
Maher et al. Partial cloning of the M subunit of laminin from adult rat lipocytes: expression of the M subunit by cells isolated from normal and injured liver
Tanaka et al. The transcription factor HNF1α regulates expression of chloride-proton exchanger ClC-5 in the renal proximal tubule
US20210236438A1 (en) Compounds and methods for the treatment of autism spectrum disorder and other neurological or psychiatric disorders
HK1045949A (en) Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk
Chen Role of peripheral CB1 cannabinoid receptors in atherosclerosis and metabolism
JP2019156718A (ja) 筋変性抑制剤及びその使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110125